Influence
April 16, 2020

Regenstrief, IU scientists describe approaches to increase care capacity for COVID-19 patients

As healthcare systems across the country prepared for an influx of patients with COVID-19, Regenstrief Institute and Indiana University Richard M. Fairbanks School of Public Health at IUPUI scientists analyzed data to provide advice on the best ways to expand treatment capacity.

The brief report was compiled by Nir Menachemi, PhD, MPH, a Regenstrief scientist and a department head at Fairbanks School of Public Health, and Jyotsna Gutta, MPH, from Fairbanks School of Public Health. The researchers examined available literature to inform decisions on the options of designating non-hospital sites to accommodate additional patients when needed and facilitating regional cooperation among hospitals to efficiently utilize resources.

Dr. Menachemi and Gutta laid out considerations for each model to help decisionmakers as they analyze the options.

You can read the report here.

Related News

Kathleen Unroe, M.D.

Barriers to Discharge for Nursing Home Residents With Serious Mental Illness

Published in the JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Kathleen T. Unroe,

Validation of a MIND diet screener in older adults

Published in Alzheimer’s & Dementia Journal. Here is a link to the article. Regenstrief Institute author: Daniel O. Clark,

Fairbanks, Lilly, Regenstrief and Indiana employers collaborate to study obesity medications’ impact

Fairbanks, Lilly, Regenstrief and Indiana employers collaborate to study obesity medications’ impact

INDIANAPOLIS — Researchers from the Fairbanks School of Public Health at Indiana University Indianapolis have launched a first-of-its-kind study

Music for the brain: Study tests the effect of slow-tempo relaxing music to address delirium in critically ill older adults

Music for the brain: Study tests the effect of slow-tempo relaxing music to address delirium in critically ill older adults

Findings support longer-duration or targeted approaches A multi-center randomized controlled trial with critically ill adults aged 50 years and